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Abstract 
 
In 2013 NHS England commissioned the use of eculizumab for both new patients 
with aHUS and those undergoing transplantation. This national service is delivered 
locally but coordinated by an expert centre at the Newcastle upon Tyne Hospitals 
NHS Foundation Trust. In the first year of the  service 43 aHUS  patients received 
eculizumab, 15 children and 28 adults.  23 were new patients and 20 prevalent.  15 of 
the 23 new patients required dialysis before eculizumab was started, 8 of these 
recovered renal function. 12 of the 20 prevalent patients who received eculizumab 
were transplant patients, 8 with  prophylactic use and 4 for recurrent disease; the 
outcome in all  was good.  Eculizumab was withdrawn in 14 patients, 5 were patients 
who had not recovered renal function. In 3 of the 14 patients it was necessary to 
reintroduce eculizumab because of recurrent disease.  There were 2 deaths in the 43 
patients,  neither was associated with use of eculizumab.  There were no episodes of 
meningococcal disease.   The establishment of this  national service has enabled 
aHUS patients in England to receive eculizumab when they need it for as long as they 
need it. 
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Introduction 
 
Atypical haemolytic uraemic syndrome (aHUS)  is an ultra-rare disease characterised 
by acute kidney injury, thrombocytopenia and microangiopathic haemolytic anaemia
1
. 
aHUS is distinguished from typical (also known as shiga toxin-producing E.coli 
[STEC]) HUS, which is associated with a preceding enterohaemorrhagic E.coli 
(EHEC) infection, by appropriate bacteriological, molecular and serological  
investigations.  The phenotypic triad can, however, be seen in other conditions where 
there is a co-existent renal thrombotic microangiopathy. Criteria have been 
established in  the UK by the aHUS rare disease group (http://rarerenal.org/rare-
disease-groups/atypical-haemolytic-uraemic-syndrome-rdg/)   for the diagnosis of  the 
disease  (Table 1). 
Approximately 50% of patients with aHUS have either an inherited and/or acquired 
abnormality of complement regulation 
1
.  Mutations have been described in genes 
encoding both complement regulators (factor H [CFH], CD46, factor I [CFI] and 
thrombomodulin [THBD]) and activators (C3 and factor B [CFB]). Autoantibodies 
against factor H and factor I have also been described.  That mutations have been 
described in aHUS in the gene (DGKE) encoding diacyl-glycerol kinase epsilon,  a 
component of the protein kinase C pathway 
2
,  suggests that not all cases of aHUS 
will have a primary underlying complement abnormality.  
Until recently the prognosis for patients presenting with aHUS was poor with the 
majority developing end-stage renal failure despite treatment with plasma exchange 
3
. 
Renal transplantation in those on dialysis is also associated with a poor prognosis with 
a high risk of recurrent disease leading to allograft failure 
4
. 
Because  the majority of patients with aHUS have an  underlying complement 
abnormality it was logical that complement inhibitors would be an appropriate 
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therapy.  Initial anecdotal reports suggested that the anti-C5 humanised monoclonal 
antibody eculizumab was highly effective and this was confirmed in subsequent open-
label studies 
5
.  The results of these studies led to approval by both the FDA and EMA 
in 2011 for the use of eculizumab in aHUS.  In England high-cost therapies (such as 
eculizumab) for very rare diseases  (such as aHUS), are usually delivered through a 
national specialised service.  An application to establish such a service for aHUS was 
first submitted to the Advisory Group for Nationalised Specialised Services (AGNSS)  
in 2011. Following evaluation of the application AGNSS submitted a report to the 
Department of Health. Based on this a statement was issued in January 2013 that 
“Ministers agreed with AGNSS that there is evidence for the clinical effectiveness of 
Eculizumab for the treatment of atypical haemolytic uraemic syndrome but wanted 
further advice on the affordability of the drug”.  The National Institute for Health and 
Care Excellence (NICE) was therefore asked to undertake an evaluation of 
eculizumab.  This process will culminate with the publication of a Final Evaluation 
Document (FED) in January 2015. The  draft FED published in December 2014 
recommends that “Eculizumab, within its marketing authorisation, is recommended 
for funding for treating atypical haemolytic uraemic syndrome, only if all the 
following arrangements are in place: coordination of eculizumab use through an 
expert centre,  monitoring systems to record the number of people with a diagnosis of 
atypical haemolytic uraemic syndrome and the number who have eculizumab, and the 
dose and duration of treatment, a national protocol for starting and stopping 
eculizumab for clinical reasons and  a research programme with robust methods to 
evaluate when stopping treatment or dose adjustment might occur 
https://www.nice.org.uk/guidance/indevelopment/gid-
atypicalhaemolyticuraemicsyndromeahuseculizumab. 
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In the meantime NHS England in 2013 resolved to  commission eculizumab  for both 
patients with newly diagnosed aHUS and also for those patients on dialysis who 
needed eculizumab to prevent the recurrence of aHUS in the transplanted kidney 
(http://www.england.nhs.uk/wp-content/uploads/2013/09/e03-hss-a.pdf).  This service 
is  delivered locally but co-ordinated by an expert centre (interim national specialised 
service) provided by the Newcastle upon Tyne Hospitals NHS Foundation Trust.  We 
here report the activity and outcomes for the first year of this service. 
 
Patients treated with eculizumab  
From the 1
st
 April 2013 to 31
st
 March 2014 43 patients received eculizumab under the 
NHS England commissioning policy. Of these  15  were  children  (aged < 18 years, 
11 male and 4 female) and  28 were adults (9 male and 19 female).  Of the 43 patients 
23 were incident (3 familial)  and 20 prevalent. 31/43 patients are still receiving 
eculizumab, treatment has been withdrawn in the remaining 12. Of the 31 patients still 
receiving eculizumab one has moved to Scotland and funding for eculizumab has 
been provided by the appropriate Health Board following submission of an individual 
patient treatment request (IPTR). 
 
Dose of eculizumab 
All adult patients received an initial dose of  900 mg via 35 minute IV infusion then 
900 mg every 7 days for the first 4 doses, followed by 1200 mg for the fifth dose 7 
days later. The maintenance dose was 1200 mg every 14 days.  The paediatric dosing 
schedule was according to weight and is shown at http://rarerenal.org/clinician-
information/haemolytic-uraemic-syndrome-atypical-ahus-clinician-
information/#Eculizumab dosage. One adult patient suffered severe migraine 
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immediately after treatment  on the maintenance dose of 1200 mg every two weeks. 
The dose was therefore decreased to 900 mg every ten days with an improvement in 
the symptoms. In another adult patient receiving eculizumab prophylactically for a 
renal transplant trough haemolytic assays showed incomplete complement blockade 
on 1200mg every two weeks with some evidence on biopsy of the transplant kidney 
of a low grade thrombotic microangiopathy. The dose of eculizumab in this patient 
was increased to 1500 mg every two weeks. 
 
 
Treatment of incident patients 
Clinicians in England who suspect a diagnosis of aHUS in a patient presenting for the 
first time are  requested to complete an aHUS diagnostic checklist (supplementary 
information).  This form requests clinical information and provides a list of 
investigations required to exclude other causes of a renal thrombotic microangiopathy. 
Clinicians are asked to submit the form electronically via nhs.net as soon as the result 
for the ADAMTS13 activity (to exclude thrombotic thrombocytopenic purpura – 
TTP) is available. This is because plasma therapy is the treatment of choice for TTP 
and should not be stopped before the diagnosis is excluded. Each submission is 
evaluated independently by the four clinicians (three adult nephrologists; THJG, NS,  
DK and one paediatric nephrologist; SJ) who oversee the interim national service to 
determine if the clinical presentation is compatible with a diagnosis of aHUS and if so 
whether treatment with eculizumab would be beneficial. In the majority of cases there 
was unanimous consensus. If this was for a diagnosis of aHUS and that eculizumab 
should be given then approval for funding was sought electronically from NHS 
England. In all cases this was obtained within 24 hours.  The local clinician was then 
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informed immediately. All the information necessary for local physicians to   initiate  
eculizumab and subsequently monitor patients is  provided at www.rarerenal.org. 
The outcome of the incident patients is shown in Figure 1. Of the 23 incident patients 
14 were adults and 9 children. All 14 adult patients  and 2 of the 9 paediatric patients 
underwent at least one session of plasma exchange or plasma infusion before 
eculizumab was given. 15 of the 23 required dialysis before starting eculizumab. 8/15 
patients requiring dialysis recovered renal function (Table 2). Eculizumab was 
continued in all except one. The longest time that any of these patients remained on 
dialysis before recovery of renal function was 30 weeks. The level of renal function 
(eGFR) that was recovered ranged from 28 to 126 ml/min/1.73m
2
. 5/15 requiring 
dialysis did not recover renal function despite at least 4 months treatment with 
eculizumab. In all these patients eculizumab was withdrawn. In all there was evidence  
(either from renal biopsy and/or renal imaging) at the time of withdrawal of 
eculizumab that there was no potential for recovery of renal function.  In two patients 
it was subsequently necessary to reintroduce eculizumab because of recurrent 
haemolysis associated with hyperkalaemia. In both this resolved with reintroduction 
of eculizumab. There were two patients on dialysis in whom eculizumab was 
withdrawn earlier. One was non-compliant with all forms of therapy including 
dialysis and in the other, a child,  both dialysis and eculizumab were withdrawn 
because of the diagnosis  of a co-existent condition (ponto cerebellar hypoplasia type 
I) which was managed conservatively.  8/23 incident patients did not require dialysis.   
Eculizumab has been withdrawn in 5. One was found to have a CD46 mutation, one 
was found to have typical HUS and three were not found to have any mutations. 
Three have continued on eculizumab.  
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Assuming a population for England of ~53 million the incidence of presumed  aHUS 
in the first year of the service was 0.43 per million population but the true incidence 
was  0.42 once the patient with typical HUS was removed. 
 
Treatment of prevalent patients on dialysis 
As of 1
st
 April 2013 there were 45 patients  (43 adults and 2 children) on dialysis in 
England with a primary renal diagnosis of aHUS.  19 of these individuals had lost a 
previous renal transplant to recurrent disease.  Mutation screening of CFH, CFI, 
CD46, C3 and CFB had been undertaken in all. In 32/45  a mutation was identified 
(CFH 13, CFI 5, C3 8, CFB 2, CFH/CFHR1 hybrid 2, CFHR1/CFH hybrid 1, 
combined CFHR1/CFH hybrid and CFI 1).  Of the 13 patients without an identified 
mutation 5 had lost a previous transplant to recurrent diseases. This suggests that in 
these individuals there is an, as of yet, unidentified inherited or acquired factor that 
has resulted in recurrent disease. All patients were also screened for factor H 
autoantibodies.  One patient who also had a CFI mutation was positive.  The majority 
of these 45 patients  were not listed for a transplant because of the risk of recurrent 
disease. The introduction of the NHS England commissioning policy for aHUS 
allowed these patients to be listed for a transplant.  NHS Blood and Transplant 
approved a proposal that retrospective weighting on the transplant list be given to 
those aHUS patients who had not been listed for a kidney transplant because of the 
risk of recurrent disease. The longest period of retrospective weighting that was given 
was 25 years.  From 1
st
 April 2013 – 31st March 2014  9/45 were transplanted.  8/9 
were given prophylactic eculizumab using a standard protocol 
(http://rarerenal.org/clinician-information/haemolytic-uraemic-syndrome-atypical-
ahus-clinician-information/#Transplantation of aHUS patients using eculizumab) and 
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1 patient received eculizumab for recurrence of the disease in the early post operative 
period.  All 9 patients have continued to receive eculizumab and have good transplant 
function. 
 
 
 
Treatment of prevalent patients not on dialysis 
8 of the 11 prevalent patients who were not on dialysis were given eculizumab to 
prevent further relapses.  The remaining three were transplant patients. One who was 
known to have a C3 mutation started eculizumab 29 months after transplant when a 
biopsy undertaken for progressive decline in transplant function showed evidence of a 
chronic thrombotic microangiopathy. With introduction of eculizumab there was an 
improvement in transplant function which has been maintained. The two other 
transplant patients had primary diagnoses of typical HUS and hypertensive end-stage 
renal disease respectively.  Both developed a thrombotic microangiopathy in the 
transplant kidney early after transplantation leading to a revised primary renal 
diagnosis of aHUS. In both there was a good response to treatment with eculizumab 
and transplant function remains stable. One was subsequently found to carry a 
pathogenic CFH mutation. 
 
Investigation  of incident and prevalent patients 
Mutation screening. 22 of the 23 incident patients underwent screening for mutations 
in CFH, CFI, CD46, C3, CFB and DKGE. The one patient who did not undergo 
screening was diagnosed as having typical HUS  within the  first week of presentation 
and received only one dose of eculizumab.  No mutations were identified in 11/22 
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patients.  In the other 11 patients there were 6 CFH, 2 CD46, 3 C3 and 1 CFI 
mutation. One patient carried both a CFH and a C3 mutation  Of the 15 incident 
patients who required dialysis before eculizumab was started 8 carried a mutation and 
7 did not. Of the 9 patients who recovered renal function 4 carried a mutation and 5 
did not.  
All  of the 20 prevalent patients had been screened for mutations in CFH, CFI, CD46, 
C3, CFB and DGKE.  18/20 carried a mutation  (8 CFH, 6 C3,  3 CFI,  1 CD46).   
Table 3 shows the mutations found in both the incident and prevalent patients. 
 
Factor H autoantibodies. Screening for factor H autoantibodies was undertaken as 
described previously
6 7
.  Six patients were found to have factor H autoantibodies 
(Table 4).  Three were prevalent and three incident.  Two patients, one incident and 
one prevalent, had borderline titres.  The remaining 4 patients, 2 prevalent and 2 
incident, had high  titres.  In all 4 multiplex ligation-dependent probe amplification 
(MLPA) analysis
8
 showed zero copies of CFHR1. Three of the 4 patients were also 
found to carry a complement gene mutation – 3   CFI (one homozygous) and 1 C3. 
 
Meningococcal disease 
Prevention of meningococcal disease was managed according to guidelines for both 
adults and children (available at http://rarerenal.org/clinician-information/haemolytic-
uraemic-syndrome-atypical-ahus-clinician-information/). The guidelines recommend 
that all patients receive a tetravalent A,C,W, Y conjugated vaccine  and the multi 
component serogroup B vaccine Bexsero. We recommend that antibody titres be 
tested at 4-6 weeks post-vaccination. In addition we recommend that all patients as 
soon as they start eculizumab receive prophylactic antibiotics which they should 
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remain on as long as they are on eculizumab.  There have been no episodes of 
meningococcal disease in any of the aHUS patients treated with eculizumab in the 
first year of the national service.  Antibody titre results for the A, C, Y and W 
serogroups are available for 10 patients. Seroprotection (serum bactericidal activity 
[SBA] titre > 8)  for all 4 serogroups was seen in 6/10 patients. In the remaining 4 
patients two had titres of < 8 for the Y serogroup, one had titres of < for 8 for the C 
and Y serogroups, and one had titres of <8 for the C and W serogroups. Revaccination 
was recommended for these 4 patients.  
Withdrawal of eculizumab 
Eculizumab was withdrawn in 14 patients (9 adults and 5 children) (Table 5).  In 5 
patients the drug was withdrawn after the patients had been on dialysis for at least 4 
months without any evidence of recovery of renal function.  In 2 of these patients it 
was necessary to restart eculizumab because of the development of significant 
haemolysis with associated hyperkalaemia. In both reintroduction of eculizumab led 
to resolution of the haemolysis.  Eculizumab was withdrawn in one patient on dialysis 
because of non-compliance with all forms of treatment including dialysis. In one 
patient eculizumab was withdrawn after only one dose because of the diagnosis of 
typical HUS.   In two patients  who presented with acute kidney injury not needing 
dialysis  with subsequent  complete recovery of renal function no mutations were 
found and eculizumab was withdrawn. There has been no recurrence of the disease in 
either of these patients. In one patient who recovered renal function after needing 
dialysis no mutations were found and eculizumab was withdrawn. Again there has 
been no recurrence of the disease in this patient. In two patients with a CD46 mutation 
eculizumab was withdrawn. In one of these patients there  was a  relapse 36 weeks 
after eculizumab was withdrawn. Eculizumab was reintroduced with complete 
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recovery of renal function and has been maintained since. In one patient eculizumab 
was withdrawn after the diagnosis of a complex neurological disorder (ponto 
cerebellar hypoplasia type I) which was treated conservatively.   
 
 
 
Monitoring the response to eculizumab 
In the clinician information at www.rarerenal.org we recommend that in addition to  
routine biochemistry and haematology investigations that all patients under go 
measurement of a pre-dose (trough) alternative pathway and classical pathway 
haemolytic assay at least twice once the patient is taking the routine long-term dose of 
eculizumab (for instance 1200mg every two weeks in adults).  We recommend that 
both assays should show no detectable haemolytic activity.  In addition we suggest 
that measurement of  platelet count, LDH,  haptoglobins and urine protein/creatinine 
ratio is undertaken  monthly. The aim of this surveillance is to ensure that 
complement blockade is complete and that there is no evidence to suggest an ongoing 
TMA. In one adult patient (known to have a pathogenic CFH mutation) receiving 
eculizumab prophylactically to enable a renal transplant there was evidence of 
incomplete complement blockade (detectable lysis on both the alternative pathway 
and classical pathway assays)  and ongoing low grade TMA on renal biopsy with 
deteriorating transplant function. This patient was receiving 1200 mg of eculizumab 
every two weeks. The dose of eculizumab was increased to 1500 mg with a 
subsequent improvement in transplant function.  Another patient (paediatric) showed 
biopsy evidence of ongoing TMA despite complete complement blockade. No 
mutations (including DGKE) were found in this patient. We also routinely screen all 
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patients for the C5 polymorphism (c.2654G>A; p.Arg885His, rs56040400) that is 
associated with resistance to eculizumab
9
. None of the patients in this cohort were 
found to carry this variant. 
 
Discussion 
The introduction of eculizumab represents a step-change in the management of 
patients with aHUS
5
. The recognition in the past two decades that most patients with 
aHUS will have either an inherited and/or acquired abnormality of complement 
leading to excessive activation of the alternative pathway has paved the way for the 
use of complement inhibitors in this disease. Eculizumab can profoundly affect the 
prognosis both for patients presenting for the first time and also those patients on 
dialysis who are unable to be transplanted because of the risk of recurrent disease. 
However, eculizumab is extremely expensive costing ~£360,000 per year for an adult 
patient.  Because of this Health Ministers in England decided after an initial 
assessment by the Advisory Group for National Specialised Service in 2013 to refer 
the drug to the National Institute for Health and Care Excellence.  The Final 
Evaluation Document produced by the Highly Specialised Evaluation Technology 
Committee affirms the clinical efficacy of eculizumab in aHUS and recommends 
funding for the use of the drug in England provided that there is coordination of its 
use through an expert centre and  monitoring systems to record the number of people 
with a diagnosis of atypical haemolytic uraemic syndrome and the number who have 
eculizumab, and the dose and duration of treatment.  We report here the experience of 
an interim national specialised service commissioned by NHS England which was 
established in 2013 and fulfils these conditions.  
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In the first year of this national service 23 patients were diagnosed for the first time as 
having aHUS and treated with eculizumab. One of these was subsequently shown to 
have typical HUS and correcting for this gives an incidence of 0.42 per million 
population.  Little information is available from other countries as to either the 
incidence or prevalence of aHUS.  Data from France for the period 2000 – 2008 based 
on the number of patients referred for screening gives an incidence of 0.23 per million 
population per year
10
.  We believe that the incidence may be higher than observed in 
the first year of this national service in England.  To date in the second year of the 
service the incidence is projected to be 0.68 per million population.   
The service that we have established is   locally-delivered with  the local clinician 
taking primary responsibility for the patient. The clinician decides if  he/she wishes to 
approach the national service for funding for eculizumab and  does this by completing 
the aHUS diagnostic checklist (supplementary information). In most cases advice has 
already been sought from one of the four clinicians responsible for the national 
service.  We are usually able to provide confirmation of funding for eculizumab, 
including approval by NHS England, within 24 hours of receiving the completed 
aHUS diagnostic checklist. On this we provide a list of tests that we suggest are 
undertaken to rule out other forms of a renal thrombotic microangiopathy. The only 
test that we require there to be a result of prior to authorisation of eculizumab is the 
ADAMTS13 activity. Most adult patients and some children have received plasma 
therapy by the time that the first dose of eculizumab is given.  
Of the 23 incident patients 16  had started dialysis by the time that eculizumab was 
started. 5 of these individuals did not recover renal function including two patients 
with a known pathogenic complement mutation (one C3 and the other a CFH/CFHR1 
hybrid gene).  Both of these individuals  had at least one other family member who 
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had been affected by the disease.   Despite   remission of the TMA in these 5 
individuals all   showed evidence (either from biopsy or serial ultrasound) of 
irreversible stage 5 CKD at the time of withdrawal of eculizumab.  All received 
eculizumab for at least 4 months. The importance of early recognition of potential 
aHUS in unaffected at-risk  family members is something that both we and the 
national patient-family support group aHUSUK (www.ahusuk.org) emphasise. We 
provide for such individuals  information in a credit card sized format which can be 
shown to healthcare professionals.  
In those patients who recovered renal function the time spent on dialysis after the start 
of eculizumab ranged from 2 to 30 weeks. In the latter case there was evidence during 
this period of increasing urine output suggesting that there was potential for recovery 
of renal function. 
Mutation screening showed that 50% of the incident patients carried a mutation in a 
known aHUS complement gene.   This is similar to the prevalence of 46% reported 
for the USA
11
 but  lower than that reported in other cross-sectional  cohorts of aHUS 
patients where up to 70% of patients  
3 10
 carry a mutation.  We have, however, not 
included in this figure disease predisposing CFH and CD46 haplotypes   or  the 
CFHR3/1 deletion.  The presence/absence of a mutation was not related to either the 
need for dialysis in incident patients or  the outcome with regard to recovery of renal 
function.  In contrast 90% of prevalent patients who received eculizumab carried a 
mutation.  The outcome in the prevalent patients was good. Prophylactic use of 
eculizumab to enable transplantation was associated with excellent transplant 
outcomes. Three patients received eculizumab post transplant. One was known to 
have aHUS as the primary disease but in the other two the primary diagnosis was 
respectively typical HUS and malignant hypertension.  We now recommend that all 
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patients on dialysis with a primary renal diagnosis of typical HUS undergo mutation 
screening.  Even in the absence of a mutation we recommend that typical HUS 
patients are counselled that there may still be a risk of developing a transplant TMA 
which would redefine the diagnosis and require treatment with eculizumab.   
Withdrawal of eculizumab in aHUS is an area where is no clear consensus. We are of 
the opinion that the evidence for lifelong treatment  with eculizumab in aHUS is not 
robust.  There is some evidence from small single cohort studies that eculizumab can 
be withdrawn in some patients without significant risk of relapse.  We think that this 
would be best addressed in a rigorous randomised controlled trial of long-term versus 
disease driven intermittent treatment.  Until such a study is established we 
recommend that the decision to withdraw treatment is taken on a case by case basis 
with input from the local physician, the national service, the patient  and his/her 
carers/family.  Guidelines for the withdrawal of treatment and subsequent monitoring 
are at www.rarerenal.org. Of the 43 patients treated in the first year of the service 
eculizumab has been withdrawn in 14 patients.  In three there has been evidence of 
recurrent disease requiring reintroduction of eculizumab. Two are dialysis patients 
who developed haemolyis and hyperkalaemia. The other was a child with a CD46 
who relapsed 36 weeks after treatment was withdrawn.  All three responded quickly 
to reintroduction of treatment. 
Another area where there is no clear consensus is what level of complement blockade  
is necessary to induce and maintain remission. The dosing regimen advocated is based 
on that used in the open label trials and was designed to completely block terminal 
pathway activity between doses. Drug levels can be used to monitor this with a 
recommended trough level of greater than 50 µg/l. Because of the logistics of 
undertaking this assay which is currently only available in the USA we do not 
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routinely undertake this. We do, however, recommend that alternative and classical 
pathway haemolytic assays are undertaken at least twice once a patient is on the 
maintenance dose of eculizumab.  We have found the information provided for these 
assays useful in two patients. Once was a transplant patient with deteriorating renal 
function who on biopsy showed evidence of low grade TMA. Haemolytic assays in 
this patient showed incomplete blockade immediately pre-dose and we, therefore, 
increased the dose of eculizumab to 1500 mg every two weeks. This was associated 
with an improvement in transplant function. The other was a child who relapsed on 
treatment. Haemolytic assays in this individual show complete blockade and we are 
suspicious there is  a non-complement mediated mechanism underlying the TMA. 
This is under further investigation. 
In conclusion; we report here the first year’s experience of a devolved national 
specialised service in England for the investigation and treatment of  patients with 
aHUS.   We believe that the activity and outcomes that we report here justify retention 
of this service on a long-term basis. We are of the opinion that locally-delivered 
national specialised services such as the one that we have established provides an 
ideal infrastructure for the management of very rare disease such as aHUS.  
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Legends to figures 
 
Figure 1.   Outcome in the incident patients.  * Eculizumab was withdrawn early in 
two of the patients needing dialysis. Both later deceased.   
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Table 1.  Diagnostic criteria for aHUS 
Exclusion 
 
Thrombotic thrombocytopenic purpura  
 
Shiga toxin associated HUS 
 
Drug mediated TMA 
 
Infection (HIV, Streptococcus pneumonia) 
 
Ttransplantation (bone marrow, liver, lung, cardiac) 
 
Cobalamin deficiency 
 
Systemic lupus erythematosis 
 
Antiphospholipid antibody syndrome  
 
Scleroderma 
 
Inclusion 
 
Renal biopsy showing a thrombotic microangiopathy 
 
and/or 
 
Triad of  microangiopathic haemolytic anaemia, thrombocytopenia and renal failure
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Table 2. Patients who required dialysis before eculizumab was started and subsequently recovered renal function 
 
Age at start of 
treatment with 
eculizumab 
(years) 
Gender Length of time on 
dialysis 
Renal function  
(eGFR ml/min/1.73m
2
) 
Mutations and/or factor H 
autoantibodies 
Eculizumab 
36 Male 19 weeks 33 CD46 (c.286+2T>G ) Continues 
25 Female 2 weeks 85 CFH(c.c.694C>T; p.Arg232*) 
and C3 (c.193A>C; 
p.Lys65Gln) 
Continues 
69 Female 9 38 Nil Continues 
33 Male 30 weeks 28 C3 (c.493G>T; p.Val165Phe) Continues 
53 Male 6 weeks 52 Nil Continues 
11 months* Male 2 weeks 126 Nil Withdrawn after 34 weeks 
3 months Male   CFH(c.1825G>A; p.Val609Ile) Continues 
3 Male   Factor H autoantibody positive Continues 
*same patient as in Table 5
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Table 3.   Mutations found in incident and prevalent patients 
Prevalent or Incident Gene Variant 
Incident CFH c.213G>A; p.Trp71* 
Incident* CFH c.694C>T; p.Arg232* 
Prevalent CFH c.942G>A; p.Trp314* 
Incident CFH c.1825G>A; p.Val609Ile 
Prevalent CFH c.1933delA;  p.Thr645fs 
Prevalent CFH c.2850G>T; p.Gln950His 
Incident CFH c.2850G>T; p.Gln950His 
Prevalent CFH c.2867C>T; p.Thr956Met 
Prevalent CFH c.3572C>T; p.Ser1191Leu 
Prevalent CFH c.3643C>G; p.Arg1215Gly 
Prevalent CFH c.3643C>G; p.Arg1215Gly 
Prevalent CFH c.3643C>G; p.Arg1215Gly 
Incident CFH c.3643C>G; p.Arg1215Gly 
Incident CFH CFH/CFHR1 hybrid 
Prevalent C3 c.193A>C; p.Lys65Gln 
Prevalent C3 c.193A>C; p.Lys65Gln 
Incident* C3 c.193A>C; p.Lys65Gln 
Prevalent C3 c.481C>T; p.Arg161Trp 
Incident C3 c.485C>G; p.Thr162Arg 
Prevalent C3 c.485C>G; p.Thr162Arg 
Incident C3 c.493G>T; p.Val165Phe 
Prevalent C3 c.3142C>G;p.Arg1042Gly 
Prevalent C3 c.3343G>A;  p.Asp1115Asn 
Incident CD46 c.286+2T>G 
Incident CD46 c.286+2T>G 
Prevalent CD46 c.646T>G; p.Trp216Gly 
Prevalent CFI c.859G>A; p.Gly287Arg 
Incident CFI c.1456T>C; p.Trp486Arg (homozygous) 
Prevalent CFI c.1733T>C; p.Ile578Thr 
*One patient carried both a CFH and a C3 mutation 
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Table 4.  Factor H autoantibody positive patients 
 
 
  
Age at start of 
treatment with 
eculizumab (years) 
Gender Prevalent/incident Autoantibody titre CFHR3 copy 
number 
CFR1 
copy 
number 
Mutations 
11 Female Prevalent +++ 0 0 CFI (c.859G>A; p.Gly287Arg) 
11 months Male Incident Borderline 2 2 Nil 
9 Female Prevalent +++ 1 0 CFI (c.1216C>T; Arg406Cys) 
17 Male Prevalent Borderline 2 2 C3 (c.3142C>G;p.Arg1042Gly) 
11 months Male Incident +++ 0 0 CFI homozygous (c.1456T>C;  
p.Trp486Arg) 
3 Male Incident +++ 0 0 Nil 
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Table 5. Patients in whom eculizumab was withdrawn 
 
Age at start of 
treatment with 
eculizumab 
(years) 
Gender Duration of 
treatment with 
eculizumab 
Dialysis Mutations Outcome 
51 Female 27 weeks Yes C3 (c.485C>G; p.Thr162Arg) 
 
Dialysis 
48 Female 24 weeks Yes Nil Dialysis.  Eculizumab reintroduced 
after six weeks because of 
haemolysis. 
21 Male 33 weeks Yes Nil Dialysis 
38 Female 19 weeks Yes Nil Dialysis 
23 Female 4 weeks Yes CFH (c.213G>A; p.Trp71*) Deceased. Non-compliant with all 
therapy. 
66 Female 16 weeks Yes Nil CKD 
31 Male 24 weeks Yes CFH/CFHR1 hybrid Dialysis. Eculizumab reintroduced 
after ten weeks because of 
haemolysis 
48 Female 26 weeks No  
Creatinine 350 µmol/l 
Nil Creatinine 77 µmol/l 
21 Female 15weeks No CD46 (c.646T>G; p.Trp216Gly) No relapses. 
5 Male 27 weeks No CD46 (c.286+2T>G) Relapsed after 36 weeks and 
eculizumab reintroduced. 
10 months Female 1 week No N/A Typical HUS. Complete recovery 
11 months* Male 34 weeks Yes Nil Complete recovery 
2 Female 26 weeks No Nil Complete recovery 
6 months Male 4 weeks Yes CFH (c.2850G>T; p. Gln950His) Deceased.  Co-existing ponto-
cerebellar hypoplasia type I. 
*same patient as in  Table 2. 
Dialysis No Dialysis 
n=15 n=8 
No recovery of 
renal function 
n=7 
Extrarenal 
relapse 
n=2 
Ecu 
reintroduced 
Recovery of 
renal function 
n=8 
Incident patients 
n=23 
Ecu 
withdrawn 
n=7* 
Ecu 
withdrawn 
n=1 
Ecu 
continued 
n=7 
Ecu 
withdrawn 
n=5 
Ecu 
continued 
n=3 
n=2 
Renal 
relapse 
n=1 
Ecu 
reintroduced 
n=1 
Dialysis dependent 
n=7 
Dialysis independent 
n=16 
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